DNA损伤修复系统与肺癌的药物治疗  

DNA Damage Repair System and Antineoplastic Agents in Lung Cancer

作　　者：张琳琳[1] 孟凡路[1] 钟殿胜[1] Linlin ZHANG;Fanlu MENG;Diansheng ZHONG(Department of Medical Oncology,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院肿瘤科,天津300052

出　　处：《中国肺癌杂志》2022年第6期434-442,共9页Chinese Journal of Lung Cancer

基　　金：国家自然科学基金(No.82103045);CSCO临床肿瘤学研究基金会科研基金(No.Y-XD202001-0332)资助。

摘　　要：DNA损伤修复(DNA damage repair,DDR)系统在维持“基因组稳定性”方面发挥重要作用。DNA损伤的累积及DDR功能减弱,都会促进肿瘤发生、发展,同时也给肿瘤的药物治疗提供机会和靶点。在肺癌治疗中,很多抗肿瘤药物发挥作用都与DNA损伤和修复密切相关。从导致DNA损伤的经典化疗药物、新型抗体偶联药物,到抑制DNA修复的靶向药物,以及免疫检查点抑制剂,这些药物在发挥抗肿瘤活性过程中,都直接或间接涉及DNA损伤及修复。本文综述了DNA损伤和修复在上述药物发挥抗肿瘤活性中的作用,并汇总了上述各类药物在肺癌治疗中的应用现状及临床探索,以期通过DNA损伤和修复为切入点,摸索更精准和有效的肺癌治疗策略。DNA damage repair(DDR)system plays an important role in maintaining of genomic stability.Accumulation of DNA lesions or deficiency of DDR system could drive tumorigenesis as well as promote tumor progression;meanwhile,they could also provide therapeutic opportunities and targets.Of all the antineoplastic agents of lung cancers,many of them targeted or were associated with DNA damage and repair pathways,such as chemotherapies and antibody-drug conjugates which were designed directly causing DNA damages,targeted drugs inhibiting DNA repair pathways,and immunecheckpoint inhibitors.In this review,we described the role of DNA damage and repair pathways in antitumor activity of the above agents,as well as summarized the application and clinical investigations of these antineoplastic agents in lung cancers,in order to provide more information for exploring precision and effective strategies for the treatment of lung cancer based on the mechanism of DNA damage and repair.

关 键 词：肺肿瘤 DNA损伤 DNA修复 抗肿瘤药物 

分 类 号：R734.2[医药卫生—肿瘤]